Revocation of Regulations Regarding the Mutual Recognition of Pharmaceutical Good Manufacturing Practice Reports, Medical Device Quality System Audit Reports, and Certain Medical Device Product Evaluation Reports: United States and the European Community
Summary
The FDA is ending an agreement with the European Union that allowed them to accept each other's inspection reports for drug manufacturing and medical devices without doing their own inspections. This means the FDA will now need to conduct its own inspections of some drugs and devices that were previously approved based on European inspections, which could affect how quickly new medications and medical products reach American patients.
Key Points
- 1The FDA is canceling a mutual recognition agreement with the European Union that previously allowed them to trust each other's quality inspections for pharmaceutical manufacturing and medical devices
- 2The FDA will no longer automatically accept European inspection reports, meaning American officials will need to conduct their own inspections of foreign manufacturing facilities
- 3This change affects drug manufacturers and medical device makers in both the United States and Europe who relied on the faster approval process under the previous agreement
- 4The revocation may slow down the approval process for some new drugs and medical devices in the U.S. market, potentially delaying patient access to new treatments
- 5Companies will need to budget for additional FDA inspections and prepare for more rigorous review processes when seeking approval in the American market
Impact Assessment
If you are a pharmaceutical or medical device manufacturer, this means you will need to accommodate additional FDA inspections of your facilities even if your products were previously approved based on European Union inspections, which increases regulatory burden and may slow product approvals.
International
Significant
Key Dates
February 19, 2026
Regulatory Connections
This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.